RT Journal Article
SR Electronic
T1 Chronic pulmonary aspergillosis incidence in newly detected pulmonary tuberculosis cases during follow-up
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.28.24303416
DO 10.1101/2024.02.28.24303416
A1 Jha, Dhouli
A1 Kumar, Umesh
A1 Meena, Ved Prakash
A1 Sethi, Prayas
A1 Singh, Amandeep
A1 Nischal, Neeraj
A1 Jorwal, Pankaj
A1 Vyas, Surabhi
A1 Singh, Gagandeep
A1 Xess, Immaculata
A1 Singh, Urvashi B
A1 Sinha, Sanjeev
A1 Mohan, Anant
A1 Wig, Naveet
A1 Kabra, Sushil Kumar
A1 Ray, Animesh
YR 2024
UL http://medrxiv.org/content/early/2024/02/29/2024.02.28.24303416.abstract
AB Background Chronic pulmonary aspergillosis (CPA) is known to complicate patients with post-tubercular lung disease. However, some evidence suggests that CPA might co-exist in patients with newly-diagnosed pulmonary tuberculosis (P.TB) at diagnosis and also develop during therapy. The objective of this study was to confirm the presence of CPA in newly diagnosed P.TB at baseline and at end-of-therapy.Materials & Methods This prospective longitudinal study included newly diagnosed P.TB patients, followed up at third month and end-of-therapy with symptom assessment, anti-Aspergillus IgG antibody and imaging of chest for diagnosing CPA.Results We recruited 255 patients at baseline out of which 158 (62%) completed their follow-up. Anti-Aspergillus IgG was positive in 11.1% at baseline and 27.8% at end-of-therapy. Overall, proven CPA was diagnosed in 7% at baseline and 14.5% at end-of-therapy. Around 6% patients had evidence of aspergilloma in CT chest at the end-of-therapy.Conclusions CPA can be present in newly diagnosed P.TB patients at diagnosis and also develop during anti-tubercular treatment. Patients with persistent symptoms or developing new symptoms during treatment for P.TB should be evaluated for CPA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission was taken from Institute Ethics Committee of All India Institute of Medical Sciences, New Delhi for the conduct of this study (IECPG-311/27.04.2022). The permission for the same was obtained on 27.04.2022.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors